Business Description
Kringle Pharma Inc
ISIN : JP3270790003
Share Class Description:
TSE:4884: Ordinary SharesDescription
Kringle Pharma Inc is engaged in the research and development of HGF (hepatocyte growth factor) protein as a therapeutic agent for intractable diseases.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.8 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 5.08 | |||||
| Beneish M-Score | -3.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -68.8 | |||||
| 3-Year EBITDA Growth Rate | -2 | |||||
| 3-Year EPS without NRI Growth Rate | -14.1 | |||||
| 3-Year FCF Growth Rate | 1.2 | |||||
| 3-Year Book Growth Rate | -15.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.59 | |||||
| 9-Day RSI | 42.31 | |||||
| 14-Day RSI | 43.82 | |||||
| 6-1 Month Momentum % | 49.13 | |||||
| 12-1 Month Momentum % | 32.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.68 | |||||
| Quick Ratio | 12.85 | |||||
| Cash Ratio | 12.56 | |||||
| Days Sales Outstanding | 76.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -14.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1207.01 | |||||
| Net Margin % | -1161.12 | |||||
| FCF Margin % | -884.29 | |||||
| ROE % | -39.66 | |||||
| ROA % | -32.13 | |||||
| ROIC % | -281.93 | |||||
| 3-Year ROIIC % | -529.3 | |||||
| ROC (Joel Greenblatt) % | -338.37 | |||||
| ROCE % | -35.6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 60.49 | |||||
| PB Ratio | 2.27 | |||||
| Price-to-Tangible-Book | 2.27 | |||||
| EV-to-EBIT | -3.21 | |||||
| EV-to-EBITDA | -3.21 | |||||
| EV-to-Revenue | 38.75 | |||||
| EV-to-FCF | -4.51 | |||||
| Price-to-Net-Current-Asset-Value | 2.27 | |||||
| Price-to-Net-Cash | 2.78 | |||||
| Earnings Yield (Greenblatt) % | -31.19 | |||||
| FCF Yield % | -12.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kringle Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 77.926 | ||
| EPS (TTM) (円) | -160.04 | ||
| Beta | 0.54 | ||
| Volatility % | 87.87 | ||
| 14-Day RSI | 43.82 | ||
| 14-Day ATR (円) | 30.812344 | ||
| 20-Day SMA (円) | 837.95 | ||
| 12-1 Month Momentum % | 32.1 | ||
| 52-Week Range (円) | 394 - 1328 | ||
| Shares Outstanding (Mil) | 6.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kringle Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kringle Pharma Inc Stock Events
| Event | Date | Price(円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kringle Pharma Inc Frequently Asked Questions
What is Kringle Pharma Inc(TSE:4884)'s stock price today?
The current price of TSE:4884 is 円810.00. The 52 week high of TSE:4884 is 円1328.00 and 52 week low is 円394.00.
When is next earnings date of Kringle Pharma Inc(TSE:4884)?
The next earnings date of Kringle Pharma Inc(TSE:4884) is .
Does Kringle Pharma Inc(TSE:4884) pay dividends? If so, how much?
Kringle Pharma Inc(TSE:4884) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers